Nishan Rajakumaraswamy

Company: Gilead Sciences

Job title: Director, Clinical Research, Oncology/ Hematology

Seminars:

Gilead Case Study: Bringing the First PI3K-δ Inhibitor to the Market 10:35 am

• Gilead’s Idelalisib was the first PI3K delta inhibitor to gain approval from the FDA in selected hematological malignancies in 2014 • Revisit the key clinical trial data leading to approval, use in the clinic along with lessons learnt, how the safety profile can be potentially optimized and some possible future directionsRead more

day: Day One